

National Immunisation Program Schedule 1 July 2020

For all Indigenous people

Age	Disease	Vaccine Brand
Indigenous children (also see influenza vaccine)		
Birth	<ul style="list-style-type: none"> Hepatitis B (usually offered in hospital)^a 	H-B-Vax [®] II Paediatric or Engerix B [®] Paediatric
2 months Can be given from 6 weeks of age	<ul style="list-style-type: none"> Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, <i>Haemophilus influenzae</i> type b (Hib) Rotavirus^b Pneumococcal Meningococcal B 	Infanrix [®] hexa Rotarix [®] Prevenar 13 [®] Bexsero [®]
4 months	<ul style="list-style-type: none"> Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, <i>Haemophilus influenzae</i> type b (Hib) Rotavirus^b Pneumococcal Meningococcal B 	Infanrix [®] hexa Rotarix [®] Prevenar 13 [®] Bexsero [®]
6 months	<ul style="list-style-type: none"> Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, <i>Haemophilus influenzae</i> type b (Hib) 	Infanrix [®] hexa
Additional dose for children in WA, NT, SA, Qld and children with specified medical risk conditions ^c	<ul style="list-style-type: none"> Pneumococcal 	Prevenar 13 [®]
Additional dose for children with specified medical risk conditions ^c	<ul style="list-style-type: none"> Meningococcal B 	Bexsero [®]
12 months	<ul style="list-style-type: none"> Meningococcal ACWY Measles, mumps, rubella Pneumococcal Meningococcal B 	Nimenrix [®] M-M-R [®] II or Priorix [®] Prevenar 13 [®] Bexsero [®]
18 months	<ul style="list-style-type: none"> <i>Haemophilus influenzae</i> type b (Hib) Measles, mumps, rubella, varicella (chickenpox) Diphtheria, tetanus, pertussis (whooping cough) 	ActHIB [®] Priorix-Tetra [®] or ProQuad [®] Infanrix [®] or Tripacel [®]
Additional vaccine for children in WA, NT, SA, Qld ^d	<ul style="list-style-type: none"> Hepatitis A 	Vaqta [®] Paediatric
4 years	<ul style="list-style-type: none"> Diphtheria, tetanus, pertussis (whooping cough), polio 	Infanrix [®] IPV or Quadracel [®]
Additional dose for children in WA, NT, SA, Qld and children with specified medical risk conditions ^c	<ul style="list-style-type: none"> Pneumococcal^e 	Pneumovax 23 [®]
Additional vaccine for children in WA, NT, SA, Qld ^f	<ul style="list-style-type: none"> Hepatitis A 	Vaqta [®] Paediatric

National Immunisation Program Schedule 1 July 2020

For all Indigenous people



A joint Australian, State and Territory Government Initiative

Age	Disease	Vaccine brand
Indigenous adolescents (also see influenza vaccine)		
12–13 years (School programs) ^g	<ul style="list-style-type: none"> Human papillomavirus (HPV)^h Diphtheria, tetanus, pertussis (whooping cough) 	Gardasil [®] 9 Boostrix [®]
14–16 years (School programs) ^g	<ul style="list-style-type: none"> Meningococcal ACWY 	Nimenrix [®]
Indigenous adults (also see influenza vaccine)		
50 years and overⁱ	<ul style="list-style-type: none"> Pneumococcal 	Prevenar 13 [®] and Pneumovax 23 [®]
70–79 years^j	<ul style="list-style-type: none"> Shingles (herpes zoster) 	Zostavax [®]
Pregnant women	<ul style="list-style-type: none"> Pertussis (whooping cough)^k Influenza^l 	Boostrix [®] or Adacel [®]
Funded annual influenza vaccination^l		

All Aboriginal and Torres Strait Islander people 6 months and over

- ^a Hepatitis B vaccine: Should be given to all infants as soon as practicable after birth. The greatest benefit is if given within 24 hours, and must be given within 7 days.
- ^b Rotavirus vaccine: First dose must be given by 14 weeks of age, the second dose by 24 weeks of age.
- ^c Risk conditions are specified in the *ATAGI clinical advice on changes to vaccine recommendations and funding for people with risk conditions from 1 July 2020*.
- ^d First dose of the 2-dose hepatitis A vaccination schedule if not previously received a dose. The second dose is now scheduled at 4 years.
- ^e Administer first dose of 23vPPV at age 4 years, followed by second dose of 23vPPV at least 5 years later.
- ^f Not required if previously received 2 doses (first dose at age ≥12 months) at least 6 months apart.
- ^g Contact your state or territory health service for school grades eligible for vaccination.
- ^h Observe Gardasil[®]9 dosing schedules by age and at-risk conditions. 2 doses: 9 to <15 years—6 months minimum interval. 3 doses: ≥15 years and/or have certain medical conditions—0, 2 and 6 month schedule. Only 2 doses funded on the NIP unless a 12–<15 year old has certain medical risk factors.
- ⁱ Administer a dose of 13vPCV, followed by first dose of 23vPPV 12 months later (2–12 months acceptable), then second dose of 23vPPV at least 5 years later.
- ^j All people aged 70 years old with a five year catch-up program for people aged 71–79 years old until 31 October 2021.
- ^k Single dose recommended each pregnancy, ideally between 20–32 weeks, but may be given up until delivery.
- ^l Refer to annual ATAGI advice on seasonal influenza vaccines.

All people aged less than 20 years are eligible for free catch-up vaccines. The number and range of vaccines and doses that are eligible for NIP funded catch-up is different for people aged less than 10 years and those aged 10–19 years. Refer to NIP catch-up fact sheets. Adult refugees and humanitarian entrants are eligible for free catch-up vaccines.

- Meningococcal B vaccine catch-up is available for all Aboriginal and Torres Strait Islander children <2 years of age for three years (until 30 June 2023). Refer to the *Australian Immunisation Handbook (the Handbook)* for dose intervals.
- People >12 months of age with conditions that increase their risk of pneumococcal disease require a dose of 13vPCV at diagnosis followed by 2 doses of 23vPPV. Refer to the *Handbook* for dose intervals. Not all risk conditions are funded under the NIP. For eligibility refer to the *ATAGI clinical advice on changes to vaccine recommendations and funding for people with risk conditions from 1 July 2020*.
- The NIP also funds vaccines for people of all ages with the following specified medical conditions (refer to the *Handbook* for dosing):
 - asplenia/hyposplenia (MenB, MenACWY, pneumococcal, and Hib if required)
 - complement deficiency (MenB, MenACWY)
 - undergoing treatment with eculizumab (MenB, MenACWY)
- Contact your State and Territory Health Department for further information on any additional immunisation programs specific to your State or Territory.

For more information

health.gov.au/immunisation

State/Territory	Contact Number
Australian Capital Territory	(02) 5124 9800
New South Wales	1300 066 055
Northern Territory	(08) 8922 8044
Queensland	13 HEALTH (13 4325 84)
South Australia	1300 232 272
Tasmania	1800 671 738
Victoria	1300 882 008
Western Australia	(08) 9321 1312